Multiple doses of the irreversible MAGL inhibitor, Lu AG06466, failed to meet the primary endpoint for treating Tourette syndrome in a phase 2 study, although it reduced the tics and premonitory urges in patients with Tourette syndrome in a single-dose phase 1b study, suggesting good tolerability [40]. Here, MGLL is linked to Tourette syndrome.